1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

MedAlliance Launches PRISTINE Study Of SELUTION SLR Drug-Eluting Peripheral Balloon

 
• By Reed Miller

SELUTION SLR is the first drug-eluting balloon accepted by the FDA as part of its breakthrough program, according to the company.

PAD. Peripheral Artery Disease acronym on sticky notes. Office desk background
• Source: shutterstock.com

The PRISTINE registry of MedAlliance Inc.’s SELUTION SLR sirolimus-eluting balloon for below-the-knee artery disease has begun in Singapore, the Swiss company announced on 12 October.

PRISTINE is a 75-patient, single-center registry at the Singapore General Hospital that is evaluating SELUTION SLR in the treatment of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By Marion Webb

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 
• By Natasha Barrow

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.